Rocket Pharmaceuticals/$RCKT
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Rocket Pharmaceuticals
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
299
ISIN
US77313F1066
Website
RCKT Metrics
BasicAdvanced
$340M
-
-$2.61
1.02
-
Price and volume
Market cap
$340M
Beta
1.02
52-week high
$26.98
52-week low
$2.19
Average daily volume
5.2M
Financial strength
Current ratio
9.19
Quick ratio
9.01
Long term debt to equity
5.454
Total debt to equity
6.151
Interest coverage (TTM)
-143.20%
Profitability
EBITDA (TTM)
-260.108
Management effectiveness
Return on assets (TTM)
-34.80%
Return on equity (TTM)
-60.45%
Valuation
Price to book
0.82
Price to tangible book (TTM)
0.97
Price to free cash flow (TTM)
-1.469
Free cash flow yield (TTM)
-68.08%
Free cash flow per share (TTM)
-215.12%
Growth
Earnings per share change (TTM)
-8.44%
3-year earnings per share growth (CAGR)
-0.99%
What the Analysts think about RCKT
Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
Bulls say / Bears say
Rocket Pharmaceuticals maintains a strong cash position of $318.2 million as of March 31, 2025, providing sufficient runway into the third quarter of 2026, which supports ongoing research and development activities. (Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results)
The company has demonstrated cost management by reducing research and development expenses to $35.9 million in Q1 2025 from $45.2 million in Q1 2024, indicating improved operational efficiency. (Rocket Pharmaceuticals Reports First Quarter 2025 Financial Results)
Analysts have set a consensus price target of $51.75 for Rocket Pharmaceuticals, reflecting confidence in the company's future prospects. (Brokerages Set Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) PT at $51.75)
The FDA has placed a clinical hold on Rocket Pharmaceuticals' mid-stage gene therapy trial for Danon disease following a patient death due to serious complications, raising concerns about the safety profile of their lead candidate. (FDA halts Rocket Pharma's gene therapy trial as complications lead to patient death)
The company reported a net loss of $258.7 million for the twelve months ended December 31, 2024, highlighting ongoing financial challenges and the need for successful commercialization of its therapies. (Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results)
Rocket Pharmaceuticals' stock experienced a significant decline of 63% in premarket trading following the FDA's clinical hold, indicating potential investor concerns about the company's future prospects. (FDA halts Rocket Pharma's gene therapy trial as complications lead to patient death)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.
RCKT Financial Performance
Revenues and expenses
RCKT Earnings Performance
Company profitability
RCKT News
AllArticlesVideos
The Gross Law Firm Reminds Rocket Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 11, 2025 – RCKT
GlobeNewsWire·17 hours ago
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RCKT
GlobeNewsWire·18 hours ago
RCKT INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewsWire·18 hours ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Rocket Pharmaceuticals stock?
Rocket Pharmaceuticals (RCKT) has a market cap of $340M as of July 11, 2025.
What is the P/E ratio for Rocket Pharmaceuticals stock?
The price to earnings (P/E) ratio for Rocket Pharmaceuticals (RCKT) stock is 0 as of July 11, 2025.
Does Rocket Pharmaceuticals stock pay dividends?
No, Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders as of July 11, 2025.
When is the next Rocket Pharmaceuticals dividend payment date?
Rocket Pharmaceuticals (RCKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Rocket Pharmaceuticals?
Rocket Pharmaceuticals (RCKT) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.